Asensus Surgical Announces St. Bernhard Hospital in Germany to Initiate Senhance Surgery Program
28 Septembre 2022 - 12:55PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced the Clinic for General and Visceral Surgery at the
St. Bernhard Hospital in Kamp-Lintfort, Germany has entered into an
agreement to lease and utilize a Senhance® Surgical System.
“We are excited to announce our partnership with St. Bernhard
Hospital as it looks to leverage cutting edge minimally invasive
surgical solutions to help improve patient outcomes. The Senhance
System’s novel intelligent capabilities coupled with the
familiarity of laparoscopy will be a great addition to the clinic,”
said Anthony Fernando, Asensus Surgical President, and CEO. “We
look forward to working with the surgical team to make their
Senhance robotic program a success.”
Asensus Surgical's technology platform, Senhance Surgical
System, is the first of its kind digital laparoscopic platform that
leverages augmented intelligence to provide unmatched performance
and patient outcomes through machine learning. Senhance goes beyond
the typical surgical robotic systems, providing surgical assurance
through haptic feedback, eye-tracking camera control, and 3D
visualization, and is the first platform to offer 3mm instruments
(the smallest instrument available in the world on a robotic
surgical platform).
In surgical procedures, haptic feedback is a highly sought after
feature which is only available on the Senhance Surgical System.
Haptic feedback gives a surgeon real-time force sensory feedback.
Not only does it allow for a more natural sensation of pressure and
tension when completing surgical tasks, but it provides an
unparalleled level of safety that other robotics platforms cannot
provide by allowing the surgeon to feel when they are in contact
with anatomy that can be potentially damaged or injured by
instrument movements.
The Senhance Surgical System is powered by the Intelligent
Surgical Unit™ (ISU™). The ISU enables real-time surgical image
analytics coupled with machine vision-driven control of the camera
for a surgeon by responding to commands and recognizing certain
objects and locations in the surgical field. It offers the surgeon
Augmented Intelligence (AI) driven control of the camera enabling
the surgeon to focus on other critical surgical tasks.
“St. Bernhard is a leader in minimally invasive surgery, with
our department being highly focused on soft tissue abdominal cases
and oncologic surgery. We are constantly looking for ways to help
our surgeons improve outcomes while at the same time reducing
invasiveness and surgical variability,” said Professor Gernot
Kaiser, Head of the Clinic for General and Visceral Surgery. “The
Senhance System will be a valuable addition to our minimally
invasive portfolio, as it expands our offering and brings
innovative features such as haptic feedback and truly first of its
kind intelligent capabilities.”
About St. Bernhard
Hospital
The St. Bernhard Hospital in Kamp-Lintfort is one of 15
hospitals managed by the “St Franziskus Stiftung Münster”, the
largest Catholic hospital group in north-west Germany. The Hospital
operates 356 beds, eleven specialist clinics and employs
approximately 850 staff who treat around 15,000 inpatients and
30,000 outpatients every year. Merging the long tradition from the
founding by the Sisters of St. Francis with today’s requirements of
the latest in treatment and care, the hospital is dedicated to
helping each patient physically, mentally, and spiritually. St.
Bernhard Hospital is known for its high-quality medical treatments,
dedication to training future nurses, and being a major employer in
Kamp-Lintfort.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit (ISU) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and St. Bernhard Hospital initiating a program with
the Senhance System. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether the Senhance Surgical System will be a great
addition to St. Bernhard Hospital and its minimally invasive
portfolio. For a discussion of the risks and uncertainties
associated with the Company’s business, please review our filings
with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the SEC on February 28, 2022 and our other filings we
make with the SEC. You are cautioned not to place undue reliance on
these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499invest@asensus.com
MEDIA CONTACT:Lauren Stredler, 847-271-6891CG
Lifelstredler@cglife.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/28609177-621b-4bfc-b002-d3859caf886b
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024